Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

Amylyx Pharmaceuticals 
Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization Application (MAA) for AMX0035 (taurursodiol]) regarding the treatment of adults with amyotrophic lateral sclerosis (ALS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Following an oral explanation held at the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.